Pharmaceuticals - Community Register


Community register of medicinal products for human use


Product information

Invented name: Laventair   
Auth. number : EU/1/14/899
Active substance : umeclidinium bromide / vilanterol trifenatate
ATC: Anatomical main group: R - Respiratory system
Therapeutic subgroup: R03 - Anti-asthmatics
Pharmacological subgroup: R03A - Adrenergics, inhalants
Chemical subgroup: R03AL - Adrenergics in combination with anticholinergics
Chemical substance: R03AL03 - Vilanterol and umeclidinium bromide
(See WHO ATC Index)
Indication: Laventair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)
Marketing Authorisation Holder: Glaxo Group Ltd
980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/05/2014 Centralised - Authorisation EMEA/H/C/3754 (2014)3179 of 08/05/2014
26/03/2015 Centralised - Variation EMEA/H/C/3754/IB/2
27/05/2015 Centralised - Notification EMEA/H/C/3754/N/5
01/10/2015 Centralised - Variation EMEA/H/C/3754/WS/823
13/01/2016 Centralised - Notification EMEA/H/C/3754/N/9
14/01/2016 Centralised - Variation EMEA/H/C/3754/WS/871/G